Haisco Pharmaceutical Group (002653.SZ): Obtained approval for the IND application for the innovative drug HSK50042

Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Shanghai Haisinuo Pharmaceutical Technology Co., Ltd., recently received a "Notice of Acceptance" from the National Medical Products Administration for the drug HSK50042 tablets. HSK50042 tablets are a self-developed oral, potent, highly selective small-molecule inhibitor drug intended for the treatment of respiratory system diseases. Preclinical studies have shown that HSK50042 effectively improves lung disease pathology symptoms in model mice at lower doses, demonstrating good efficacy, tolerability, and a wide safety margin. It is a drug with great development potential and is expected to provide a new, effective, and safe treatment option for patients with respiratory diseases.